{{Rsnum
|rsid=335251
|Gene=PSD3
|Chromosome=8
|position=18789828
|Orientation=minus
|GMAF=0.4683
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=PSD3
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 32.3 | 52.3 | 15.4
| HCB | 17.8 | 55.6 | 26.7
| JPT | 11.4 | 47.7 | 40.9
| YRI | 15.9 | 42.9 | 41.3
| ASW | 0.0 | 0.0 | 0.0
| CHB | 17.8 | 55.6 | 26.7
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs335251
|Name_s=
|Gene_s=PSD3
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.40, combined P value= 1.85E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470205
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs335251
|overall_frequency_n=62
|overall_frequency_d=128
|overall_frequency=0.484375
|n_genomes=39
|n_genomes_annotated=0
|n_haplomes=57
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}